Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Total Liabilities (2020 - 2026)

Nautilus Biotechnology has reported Total Liabilities over the past 7 years, most recently at $33.4 million for Q1 2026.

  • Quarterly results put Total Liabilities at $33.4 million for Q1 2026, changed 0.33% from a year ago — trailing twelve months through Mar 2026 was $33.4 million (changed 0.33% YoY), and the annual figure for FY2025 was $34.1 million, changed 0.37%.
  • Total Liabilities reached $33.4 million in Q1 2026 per NAUT's latest filing, down from $34.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $42.2 million in Q1 2023 and bottomed at $31.8 million in Q3 2025.
  • Median Total Liabilities over the past 5 years was $35.0 million (2022), compared with a mean of $36.1 million.
  • The largest annual shift saw Total Liabilities skyrocketed 956.92% in 2022 before it decreased 15.42% in 2024.
  • Over 5 years, Total Liabilities stood at $35.1 million in 2022, then increased by 14.47% to $40.2 million in 2023, then fell by 15.42% to $34.0 million in 2024, then increased by 0.37% to $34.1 million in 2025, then decreased by 2.27% to $33.4 million in 2026.
  • Business Quant data shows Total Liabilities for NAUT at $33.4 million in Q1 2026, $34.1 million in Q4 2025, and $31.8 million in Q3 2025.